SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Attention centers on SELLASs Phase 3 REGAL topline results for GPS, with managements stated November timeline intensifying focus on the final analysis. Traders are split between optimistic expectations and short-squeeze speculation versus concerns about the binary outcome, delays, and recent share-price weakness.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention after quarterly results and an upbeat revenue outlook, with traders highlighting cloud growth and a reported Microsoft deal. Bulls emphasize the raised guidance and AI demand, while skeptics point to widening losses, heavy spending, and whether growth justifies the valuation.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel pushed its planned prostate-cancer BLA filing to mid-2027 amid assay-refinement work and ongoing FDA discussions, prompting a sharp selloff and concerns about management credibility and possible dilution. Some traders view it as a CMC delay rather than a rejection, arguing that the Phase 3 results remain unchanged.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Ciscos quarterly earnings beat and raised full-year outlook, including stronger AI infrastructure expectations, are driving attention. Traders are split between optimism about networking demand and frustration that the stocks reaction has been muted and volatile, with some questioning margins and whether AI orders will translate into sustained revenue.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

A disappointing third-quarter report, softer sequential ANKTIVA sales, and concerns about cash burn, possible dilution, and limited management guidance are driving the selloff discussion. Some traders view the reaction as excessive and point to the positive BCG-nave trial result and potential expansion, while others question commercial execution and the funding outlook.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Nu Holdings is drawing attention after its Q3 earnings report, with traders weighing strong revenue and profit growth and improving efficiency against concerns about rising delinquencies, credit quality, and whether the results met expectations. Reactions are split, with some viewing the selloff despite solid results as an overreaction and others seeing weaker credit metrics and muted stock performance as reasons for caution.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Anthropics Claude Sheets and other workplace tools are fueling concern that competition could pressure Microsoft 365 and Copilot, with traders linking the launch to weakness in MSFT shares. The debate is whether new AI tools can displace deeply embedded enterprise software or pose only a limited threat to Microsofts established workflows.

Cardinal Infrastructure Group, Inc. provides infrastructure services to the residential, commercial, industrial, municipal, and state infrastructure markets. It delivers wet utility installations of water, sewer, and stormwater systems, as well as grading, site clearing, erosion control, drilling and blasting, paving, and other related site services. The company was founded on June 12, 2025 and is headquartered in Raleigh, NC.

Cardinal Infrastructure Group Inc - Ordinary Shares - Class A

A sharp selloff followed Cardinals weak quarterly results, withdrawn full-year guidance and disclosure that its CFO plans to leave, with traders focused on worsening project margins and managements execution. The community is split between concerns about further deterioration and bankruptcy risk, and hopes that the stock is oversold and the authorized buyback could support a recovery; the authorization does not confirm that repurchases have begun.

Applied Materials, Inc. engages in provision of materials engineering solutions used to produce semiconductors. The firm also focuses on design, development, production, and servicing of the critical wafer fabrication tools used for customers to manufacture semiconductors. It operates through the following segments: Semiconductor Systems and Applied Global Services (AGS). The Semiconductor Systems segment includes designing, development, manufacturing and sale of equipment used to fabricate semiconductor chips referred to as integrated circuits. The AGS segment engages in provision of services, spares, and factory automation software to customer fabrication plants globally. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

Applied Materials quarterly results topped expectations and its next-quarter outlook was stronger than consensus, but the shares barely responded and sold off. Traders are debating whether the good news was already priced in, with some questioning how strong the guidance looks after adjusting for an extra week in the quarter; others point to options volatility and broader weakness in chip stocks.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

Hot inflation data has strengthened the dollar and Treasury yields, fueling expectations of tighter Fed policy and pressure on non-yielding gold; GLD has sold off sharply toward its recent lows. Traders are divided between expecting further downside and buying the dip, with some arguing that debt and inflation risks support gold over the longer term.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Hepion Pharma Stock Draws Bullish Retail Bets Despite Nasdaq Delisting Notice: 'Could Get Interesting'

Equity

Despite a sharp decline in stock price, retail traders are optimistic about the company's potential, citing its core asset Rencofilstat and speculating on a rebound following the OTC transition.

Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate, Rencofilstat, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Morristown, NJ.

Hepion Pharmaceuticals Inc

Bearish Sentiment

Shares of Hepion Pharmaceuticals Inc. drew heightened attention from retail traders on Monday after the company disclosed that the Nasdaq Hearings Panel had ordered its delisting, citing violations of continued listing requirements.&nbsp;Trading in the company's common stock is set to be suspended at the open on Tuesday, with shares expected to move to the OTC Markets under the same ticker, HEPA.Hepion Pharmaceuticals shares closed down 18.8% at $0.32 on Monday, sliding 45% to $0.17 in after-hours trading.Retail sentiment on Stocktwits turned 'bullish' on Monday amid a 5,100% surge in 24-hour message volume.One user highlighted optimism around Hepion's core asset, Rencofilstat, describing it as a potentially "revolutionary" drug class.&nbsp;Rencofilstat is a cyclophilin inhibitor aimed at treating chronic liver diseases like NASH and hepatocellular carcinoma (HCC).The user suggested that although trial results may not be released soon, the drug could eventually displace existing therapies once they have been fully monetized.&nbsp;They added that the move to OTC "could get interesting."<stembedurl>https://stocktwits.com/BADBOYROY/message/614371348</stembedurl>Another user hoped the stock would be tradable on Robinhood after moving to the OTC market, suggesting the transition could trigger a strong upward move.<stembedurl>https://stocktwits.com/stock_trafficking/message/614386549</stembedurl>The delisting followed Nasdaq's determination that Hepion had failed to maintain the minimum bid price of $1.00 and was in breach of Rule 5101, which allows delisting of companies identified as public shells.Hepion recently entered a license agreement with New Day Diagnostics LLC to distribute tests for celiac disease, respiratory multiplex (COVID-19, Influenza A/B, RSV), H. pylori, and hepatocellular carcinoma (HCC).&nbsp;These tests carry CE marks, making them eligible for sale in Europe.The company had previously paused and then wound down its ASCEND-NASH Phase 2b trial for Rencofilstat, after enrolling 151 patients out of a planned 336.&nbsp;Approximately 80 patients completed a full year of treatment.The stock has declined 98.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic picture shows a hand holidng a capsule on 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Nvidia ($NVDA) is moving lower after Jensen Huang resigned as CEO. Are you buying the dip?

Stocktwits

) is moving lower after Jensen Huang resigned as CEO. Are you buying the dip?

Current Price	$0.14
Prev Close	$0.13
Open	$0.12
Dividend Yield	0.00%
50-Day Moving Average	$0.1047
Beta	0.35
Avg. Volume	25,372.14
PE Ratio	-0.53

52-Week High	$0.22
52-Week Low	$0.0341
Market Capitalization	$12.77M
EPS (Annual)	-$0.8797
Price to Book	-9.08
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

HEPA Fundamentals